Sex Differences in Dopamine Receptor Signaling in Fmr1 Knockout Mice: A Pilot Study
Abstract
:1. Introduction
2. Materials and Methods
2.1. Animals
2.2. Drug Treatment
2.3. Total Protein Isolation and Sample Preparation
2.4. Western Blot
2.5. Statistical Analysis
3. Results
3.1. Fmr1-KO Animals Have Reduced Dopamine D1 Receptor-Mediated Signaling
3.2. Sex Differences in Phosphorylated PKA and GSK-3β Are Lost in Fmr1-KO Mice
3.3. L-Stepholidine Has Different Effects on Male and Female Wild-Type Mice
3.4. L- Stepholidine Has Different Effects in Male and Female Fmr1-KO Mice
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Hagerman, R.J.; Polussa, J. Treatment of the psychiatric problems associated with fragile X syndrome. Curr. Opin. Psychiatry 2015, 28, 107–112. [Google Scholar] [CrossRef]
- Wang, T.; Bray, S.M.; Warren, S.T. New perspectives on the biology of fragile X syndrome. Curr. Opin. Genet. Dev. 2012, 22, 256–263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ciaccio, C.; Fontana, L.; Milani, D.; Tabano, S.; Miozzo, M.; Esposito, S. Fragile X syndrome: A review of clinical and molecular diagnoses. Ital. J. Pediatr. 2017, 43, 39. [Google Scholar]
- Budimirovic, D.B.; Subramanian, M. Neurobiology of Disease, in Neurobiology of Autism and Intellectual Disability: Fragile X Syndrome: Fragile X Syndrome; Oxford University Press: Oxford, UK, 2017. [Google Scholar]
- Budimirovic, D.B.; Schlageter, A.; Filipovic-Sadic, S.; Protic, D.D.; Bram, E.; Mahone, E.M.; Nicholson, K.; Culp, K.; Javanmardi, K.; Kemppainen, J.; et al. A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments. Brain Sci. 2020, 10, 694. [Google Scholar] [CrossRef]
- CDC. Facts about Fragile X Syndrome. Available online: https://www.cdc.gov/ncbddd/fxs/facts.html (accessed on 23 October 2021).
- NICHD. Therapy Treatments. Available online: https://www.nichd.nih.gov/health/topics/fragilex/conditioninfo/therapytreatments (accessed on 23 October 2021).
- NICHD. Medication Treatments. Available online: https://www.nichd.nih.gov/health/topics/fragilex/conditioninfo/medicationtreatments (accessed on 23 October 2021).
- Hagerman, R.J.; Berry-Kravis, E.; Kaufmann, W.E.; Ono, M.Y.; Tartaglia, N.; Lachiewicz, A.; Kronk, R.; Delahunty, C.; Hessl, D.; Visootsak, J.; et al. Advances in the Treatment of Fragile X Syndrome. Pediatrics 2009, 123, 378–390. [Google Scholar] [PubMed] [Green Version]
- Berry-Kravis, E.M.; Lindemann, L.; Jønch, A.E.; Apostol, G.; Bear, M.F.; Carpenter, R.L.; Crawley, J.N.; Curie, A.; Portes, V.D.; Hossain, F.; et al. Drug development for neurodevelopmental disorders: Lessons learned from fragile X syndrome. Nat. Rev. Drug Discov. 2017, 17, 280–299. [Google Scholar] [PubMed] [Green Version]
- Duy, P.Q.; Budimirovic, D.B. Fragile X syndrome: Lessons learned from the most translated neurodevelopmental disorder in clinical trials. Transl. Neurosci. 2017, 8, 7–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fu, Y.-H.; Kuhl, D.P.; Pizzuti, A.; Pieretti, M.; Sutcliffe, J.S.; Richards, S.; Verkert, A.J.; Holden, J.J.; Fenwick, R.G.; Warren, S.T.; et al. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 1991, 67, 1047–1058. [Google Scholar]
- Pieretti, M.; Zhang, F.; Fu, Y.-H.; Warren, S.T.; Oostra, B.A.; Caskey, C.; Nelson, D.L. Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 66, 817–822. [Google Scholar]
- Verheij, C.; Bakker, C.E.; De Graaff, E.; Keulemans, J.; Willemsen, R.; Verkerk, A.J.M.H.; Galjaard, H.; Reuser, A.; Hoogeveen, A.T.; Oostra, B.A. Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 1993, 363, 722–724. [Google Scholar] [CrossRef]
- Coffee, B.; Zhang, F.; Warren, S.T.; Reines, D. Acetylated histones are associated with FMR1 in normal but not fragile X-syndrome cells. Nat. Genet. 1999, 22, 98–101. [Google Scholar] [PubMed]
- Coffee, B.; Zhang, F.; Ceman, S.; Warren, S.T.; Reines, D. Histone Modifications Depict an Aberrantly Heterochromatinized FMR1 Gene in Fragile X Syndrome. Am. J. Hum. Genet. 2002, 71, 923–932. [Google Scholar] [PubMed] [Green Version]
- Fatemi, S.H.; Kneeland, R.E.; Liesch, S.B.; Folsom, T.D. Fragile X mental retardation protein levels are decreased in major psychiatric disorders. Schizophr. Res. 2010, 124, 246–247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hunter, J.; Rivero-Arias, O.; Angelov, A.; Kim, E.; Fotheringham, I.; Leal, J. Epidemiology of fragile X syndrome: A systematic review and meta-analysis. Am. J. Med. Genet. Part A 2014, 164, 1648–1658. [Google Scholar]
- Hagerman, P.J. The fragile X prevalence paradox. J. Med. Genet. 2008, 45, 498–499. [Google Scholar] [CrossRef] [PubMed]
- Crawford, D.; Acuna, J.; Sherman, S.L. FMR1 and the fragile X syndrome: Human genome epidemiology review. Genet. Med. 2001, 3, 359–371. [Google Scholar]
- Hagerman, R.J.; Berry-Kravis, E.; Hazlett, H.C.; Bailey, D.B.; Moine, H.; Kooy, R.F.; Tassone, F.; Gantois, I.; Sonenberg, N.; Mandel, J.L.; et al. Fragile X syndrome. Nat. Rev. Dis. Primers 2017, 3, 17065. [Google Scholar]
- Bartholomay, K.L.; Lee, C.H.; Bruno, J.L.; Lightbody, A.A.; Reiss, A.L. Closing the Gender Gap in Fragile X Syndrome: Review on Females with FXS and Preliminary Research Findings. Brain Sci. 2019, 9, 11. [Google Scholar] [CrossRef] [Green Version]
- Nolan, S.O.; Reynolds, C.D.; Smith, G.D.; Holley, A.; Escobar, B.; Chandler, M.A.; Volquardsen, M.; Jefferson, T.; Pandian, A.; Smith, T.; et al. Deletion of Fmr1 results in sex-specific changes in behavior. Brain Behav. 2017, 7, e00800. [Google Scholar]
- Hatton, D.D.; Hooper, S.R.; Bailey, D.B.; Skinner, M.L.; Sullivan, K.M.; Wheeler, A. Problem behavior in boys with fragile X syndrome. Am. J. Med. Genet. 2002, 108, 105–116. [Google Scholar] [CrossRef] [PubMed]
- Sullivan, K.; Hatton, D.D.; Hammer, J.; Sideris, J.; Hooper, S.; Ornstein, P.A.; Bailey, D.B. Sustained attention and response inhibition in boys with fragile X syndrome: Measures of continuous performance. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2007, 144B, 517–532. [Google Scholar] [CrossRef] [PubMed]
- Reynolds, C.D.; Nolan, S.O.; Jefferson, T.; Lugo, J.N. Sex-specific and genotype-specific differences in vocalization development in FMR1 knockout mice. NeuroReport 2016, 27, 1331–1335. [Google Scholar] [CrossRef] [Green Version]
- Wang, H.; Wu, L.-J.; Kim, S.S.; Lee, F.J.; Gong, B.; Toyoda, H.; Ren, M.; Shang, Y.-Z.; Xu, H.; Liu, F.; et al. FMRP Acts as a Key Messenger for Dopamine Modulation in the Forebrain. Neuron 2008, 59, 634–647. [Google Scholar] [PubMed] [Green Version]
- Paul, K.; Venkitaramani, D.V.; Cox, C.L. Dampened dopamine-mediated neuromodulation in prefrontal cortex of fragile X mice. J. Physiol. 2013, 591, 1133–1143. [Google Scholar] [PubMed]
- Beaulieu, J.M.; Sotnikova, T.D.; Marion, S.; Lefkowitz, R.J.; Gainetdinov, R.R.; Caron, M.G. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 2005, 122, 261–273. [Google Scholar] [CrossRef] [Green Version]
- Beaulieu, J.-M.; Gainetdinov, R.; Caron, M.G. The Akt–GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28, 166–172. [Google Scholar] [PubMed]
- Jin, G.-Z.; Zhu, Z.-T.; Fu, Y. (−)-Stepholidine: A potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions. Trends Pharmacol. Sci. 2002, 23, 4–7. [Google Scholar] [PubMed]
- Natesan, S.; Reckless, G.E.; Barlow, K.B.L.; Odontiadis, J.; Nobrega, J.N.; Baker, G.B.; George, S.R.; Mamo, D.; Kapur, S. The antipsychotic potential of l-stepholidine—A naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacologia 2008, 199, 275–289. [Google Scholar]
- Wang, W.; Zhou, Y.; Sun, J.; Pan, L.; Kang, L.; Dai, Z.; Yu, R.; Jin, G.; Ma, L. The effect of l-stepholidine, a novel extract of Chinese herb, on the acquisition, expression, maintenance, and re-acquisition of morphine conditioned place preference in rats. Neuropharmacology 2007, 52, 355–361. [Google Scholar]
- Zhou, M.; Gong, X.; Ru, Q.; Xiong, Q.; Chen, L.; Si, Y.; Xiao, H.; Li, C. The Neuroprotective Effect of L-Stepholidine on Methamphetamine-Induced Memory Deficits in Mice. Neurotox. Res. 2019, 36, 376–386. [Google Scholar] [PubMed]
- Hao, J.-R.; Sun, N.; Lei, L.; Li, X.-Y.; Yao, B.; Sun, K.; Hu, R.; Zhang, X.; Shi, X.-D.; Gao, C. L-Stepholidine rescues memory deficit and synaptic plasticity in models of Alzheimer’s disease via activating dopamine D1 receptor/PKA signaling pathway. Cell Death Dis. 2015, 6, e1965. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kaasinen, V.; Någren, K.; Hietala, J.; Farde, L.; Rinne, J.O. Sex Differences in Extrastriatal Dopamine D2-Like Receptors in the Human Brain. Am. J. Psychiatry 2001, 158, 308–311. [Google Scholar] [CrossRef]
- Zachry, J.E.; Nolan, S.O.; Brady, L.J.; Kelly, S.J.; Siciliano, C.A.; Calipari, E.S. Sex differences in dopamine release regulation in the striatum. Neuropsychopharmacology 2020, 46, 491–499. [Google Scholar]
- Hasbi, A.; Nguyen, T.; Rahal, H.; Manduca, J.D.; Miksys, S.; Tyndale, R.F.; Madras, B.K.; Perreault, M.L.; George, S.R. Sex difference in dopamine D1-D2 receptor complex expression and signaling affects depression- and anxiety-like behaviors. Biol. Sex Differ. 2020, 11, 1–17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eliez, S.; Blasey, C.M.; Freund, L.S.; Hastie, T.; Reiss, A.L. Brain anatomy, gender and IQ in children and adolescents with fragile X syndrome. Brain 2001, 124, 1610–1618. [Google Scholar] [CrossRef] [Green Version]
- Murphy, M.M.; Abbeduto, L. Gender differences in repetitive language in fragile X syndrome. J. Intellect. Disabil. Res. 2007, 51, 387–400. [Google Scholar]
- Berry-Kravis, E. Epilepsy in fragile X syndrome. Dev. Med. Child Neurol. 2007, 44, 724–728. [Google Scholar] [CrossRef]
- Kucka, M.; Tomić, M.; Bjelobaba, I.; Stojilkovic, S.S.; Budimirovic, D.B. Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs. Sci. Rep. 2015, 5, 8902. [Google Scholar] [CrossRef] [Green Version]
- Dominick, K.C.; Wink, L.K.; Pedapati, E.V.; Shaffer, R.; Sweeney, J.A.; Erickson, C.A. Risperidone Treatment for Irritability in Fragile X Syndrome. J. Child Adolesc. Psychopharmacol. 2018, 28, 274–278. [Google Scholar]
- Erickson, C.A.; Stigler, K.A.; Posey, D.J.; McDougle, C.J. Aripiprazole in autism spectrum disorders and fragile X syndrome. Neurotherapeutics 2010, 7, 258–263. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hess, L.G.; Fitzpatrick, S.E.; Nguyen, D.V.; Chen, Y.; Gaul, K.N.; Schneider, A.; Chitwood, K.L.; Eldeeb, M.A.a.; Polussa, J.; Hessl, D.; et al. A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. J. Dev. Behav. Pediatrics 2016, 37, 619–628. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jiang, A.; Wang, L.; Lu, J.Y.D.; Freeman, A.; Campbell, C.; Su, P.; Wong, A.H.C.; Liu, F. Sex Differences in Dopamine Receptor Signaling in Fmr1 Knockout Mice: A Pilot Study. Brain Sci. 2021, 11, 1398. https://doi.org/10.3390/brainsci11111398
Jiang A, Wang L, Lu JYD, Freeman A, Campbell C, Su P, Wong AHC, Liu F. Sex Differences in Dopamine Receptor Signaling in Fmr1 Knockout Mice: A Pilot Study. Brain Sciences. 2021; 11(11):1398. https://doi.org/10.3390/brainsci11111398
Chicago/Turabian StyleJiang, Anlong, Le Wang, Justin Y. D. Lu, Amy Freeman, Charlie Campbell, Ping Su, Albert H. C. Wong, and Fang Liu. 2021. "Sex Differences in Dopamine Receptor Signaling in Fmr1 Knockout Mice: A Pilot Study" Brain Sciences 11, no. 11: 1398. https://doi.org/10.3390/brainsci11111398